Teva faces generic Copaxone a year early


Shares of Teva Pharmaceutical (TEVA -2.2%) are lower after the U.S. Court of Appeals invalidates a 2015 Copaxone patent.

The company expects the FDA to approve a longer-acting version of the drug early next year and had planned to spend 2014 converting patients to the new dosage. With generic competition now possible in less than a year, TEVA's original plan is now "de facto impossible," according to one hedge fund manager quoted by Bloomberg.

Previously: Momenta Pharmaceuticals soars on Copaxone ruling.

From other sites
Comments (2)
  • doc47
    , contributor
    Comments (1511) | Send Message
     
    Really sick of reading about the mistakes, miscalculations, and pie-in-the-sky "experts'" predictions for this stock. I'm going to greener pastures where management has at least half a brain. Good luck to all.
    29 Jul 2013, 03:22 PM Reply Like
  • bnkd
    , contributor
    Comments (54) | Send Message
     
    Any credence to Teva saying it is a very complex molecule and difficult to copy copoxone, generic company will have to do clinical
    trial to get FDA approval ?
    29 Jul 2013, 07:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs